These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19582472)

  • 41. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
    Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
    Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anterior ischemic optic neuropathy following intravitreal bevacizumab.
    Huang JY; Ozaki H; Hayashi H; Uchio E
    Jpn J Ophthalmol; 2010 May; 54(3):252-4. PubMed ID: 20577866
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
    Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
    Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population.
    Kumar A; Sinha S
    Indian J Ophthalmol; 2007; 55(6):451-5. PubMed ID: 17951903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
    Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
    Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resolution of diabetic papillopathy after a single intravitreal injection of ranibizumab.
    Willerslev A; Munch IC; Larsen M
    Acta Ophthalmol; 2012 Aug; 90(5):e407-9. PubMed ID: 22268957
    [No Abstract]   [Full Text] [Related]  

  • 47. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion.
    Chung EJ; Hong YT; Lee SC; Kwon OW; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2008 Sep; 246(9):1241-7. PubMed ID: 18546006
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye.
    Karth PA; Chang A; Wirostko W
    Graefes Arch Clin Exp Ophthalmol; 2014 Feb; 252(2):207-11. PubMed ID: 23873254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
    Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
    Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema.
    Barone A; Russo V; Prascina F; Delle Noci N
    Retina; 2009 Jan; 29(1):33-7. PubMed ID: 18854783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CORRELATION OF OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI WITH VISUAL OUTCOMES IN DIFFERENT PATTERNS OF DIABETIC MACULAR EDEMA.
    Kang JW; Chung H; Chan Kim H
    Retina; 2016 Sep; 36(9):1630-9. PubMed ID: 26900741
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease.
    Mirshahi A; Namavari A; Djalilian A; Moharamzad Y; Chams H
    Ocul Immunol Inflamm; 2009; 17(1):59-64. PubMed ID: 19294576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
    Ozkiriş A
    Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis.
    Moon SJ; Berger AS; Tolentino MJ; Misch DM
    Ophthalmic Surg Lasers Imaging; 2007; 38(2):164-6. PubMed ID: 17396701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
    Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
    Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
    Michaelides M; Kaines A; Hamilton RD; Fraser-Bell S; Rajendram R; Quhill F; Boos CJ; Xing W; Egan C; Peto T; Bunce C; Leslie RD; Hykin PG
    Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
    Kim M; Lee P; Kim Y; Yu SY; Kwak HW
    Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia.
    Matsumoto Y; Yuzawa M
    Jpn J Ophthalmol; 2010 Jul; 54(4):320-4. PubMed ID: 20700800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.